Purpose: We aimed to evaluate and compare the efficacy and safety of high-dose furosemide+salt orally by comparing HSS+ furosemide (i.v.) and repeated paracentesis in patients with RA.
Cirrhosis is a severe scarring of the liver and poor liver function seen at the terminal stages of chronic liver disease. Progression of chronic liver disease to liver cirrhosis varies and depends on the etiology and the patient. The main form of treatment is liver transplantation, but many patients with this complication receive palliative therapies, among which therapeutic paracentesis is the frequently used.
Decompensated cirrhosis has one or several of the following findings: ascites, esophageal varicose bleeding, hepatic encephalopathy (HE), spontaneous bacterial peritonitis (SBP), hepatocellular carcinoma, hepatorenal syndrome, hepatopulmonary syndrome and hypersplenism and hematological disorders [1, 2] . One of the most important findings is the presence of ascites -the accumulation of fluid in the pleural cavity and/or in the peritoneal cavity [3] . In patients with cirrhosis, ascites is defined as refractory when it can not be mobilized or recurs early in standard diuretic therapy. Refractory ascites (RA) is a critical and difficult-to-treat complication of advanced liver cirrhosis and 50% of such patients die within 6 months of its beginning [4, 5] .
Technically, RA is defined as ascites that cannot be mobilized or the early recurrence of which cannot be satisfactorily prevented by lack of response to sodiumrestricted diet and high-dose diuretic treatment (160 mg/day furosemide and 400 mg/day of spironolactone) or development of diuretic-induced complications to preclude using effective diuretic dosage [4] . The diuretic-induced complications include HE, serum creatinine levels more than 2 mg/dL, serum sodium level less than 125 mEq/L (hyponatremia) and serum potassium level less than 3 mEq/L or greater than 6 mEq/L and possible kidney failure [6] .
For ascites grade II and III patients, the fluid accumulation in the peritoneal and/or pleural cavity can be controlled with salt restriction, bed rest and oral diuretic therapy. Daily sodium intake in the salt-free diet is kept below 200 mg [6, 7] . With bed rest, lying position eliminates increase of aldosterone secretion caused by postural changes. Diuretic treatment within a few weeks or may recurred ascites. For patients in this situation, there are a variety of therapeutic options that may b e e n a t t e m p t e d : t h e r a p e u t i c r e p e a t e d large-volume-paracentesis (PLVP) accompanied with intermittent i.v. albumin, transjugular intrahepatic portosystemic shunt (TIPS) and liver transplantation [8] .
The prevalence and incidence of cirrhosis with RA are progressively increasing worldwide, and new medical strategies are needed for the treatment of patients. Recently, a new treatment approach has been developed: HSS (150 mL H 2 O with 1.4-4.6 % NaCl solution) with high-dose i.v. furosemide (250-1000 mg bid i.v.). According to the a case report, HSS leads to increased renal blood flow and reduced sympathetic tone, so it has the potential to be an effective treatment for RA [9] .
The goal of this study was to evaluate the success and the reliability of treatment approach of salt orally+high-dose diuretics. Our evaluation criteria are a reduction in body weight, improvement of Child-Pugh and MELD (model of end stage liver disease) score, decrease in duration of hospital stay and number of hospitalization, decrease in serum sodium levels and improvement in any-coexisting fluid and HE.
Materials and Methods

Patients
Seventy eight (47 male and 31 female, 35-85 years) cirrhotic patients with RA who had been admitted to the Gastroenterology units of Baskent University Hospital in Adana and the Gastroenterology units of Mustafa Kemal University Medical Faculty in Hatay, Turkey; between January 2012 and November 2015, were studied retrospectively. Enrollment in the study was offered to them after the diagnosis of RA. All patients were evaluated with clinical examination, routine hematological, biochemical, serological investigations and abdominal USG.
Eligibility criteria
Diagnosis was based on the following diagnostic criteria for RA which was defined by the IAC criteria1 [10] as one of the following: (a) Diuretic-resistant RA: <1.5 kg⁄ week weight loss while being treated with furosemide (160 mg⁄ day) and spironolactone (400 mg⁄ day) or an equivalent dose of a loop-acting and distal-acting diuretic; (b) Diuretic-intractable RA: <1.5 kg⁄ week weight loss as a result of the inability to use an effective dose of diuretic because of development of diuretic-induced hyponatremia (sodium level <125 mEq⁄ L), hyperkalemia (potassium level >5.5 mEq⁄ L), renal failure (doubling of serum creatinine level >2.5 g ⁄ dL) or encephalopathy; or, (c) Previous dietary restriction of sodium between 50 and 66 mEq ⁄ day.
Patients had been identified as diuretic-resistant ascites (patient'sascites cannot be controlled despite salt restriction+maximal dose of diuretic therapy) and diuretic-intractable ascites (patients were unable to use effective doses of diuretics because of side effects of diuretic). 
Study Design
Group A: Spironolactone tablets (1x100 mg/day fixed dose) and i.v. infusion of furosemide (2x240 mg/day) (speed not exceeding 4 mg/min) was applied. If reduction of daily weight was less than 500 g, dose increased 2x300 mg on the 2 nd day and if there was still not the desired weight loss, then dose increased 2x360 mg on the 3 rd . After sufficient diuresis level has been captured, the patient was kept in the hospital until ascites evidence (Phase II) had clinically disappeared. HSS: 150 ml of 3% NaCl was given as a single dose by infusion over 30 min the morning of the day in which furosemide was given. Group B: On the 1 st day, spironolactone tablet 1x100 mg/day fixed dose and furosemide tablet 2x360 mg dose were administered. If the reduction of daily weight was less than 500 g, on 2 nd day 2x440 mg dose was administered. If desired weight loss had still not been reached, on 3 rd day 2x520 mg dose increases were administered. After sufficient diuresis level had been realized, the patient was kept in the hospital until ascites evidence (Phase II) clinically disappeared. Oral Salt: Added into a glass of unsalted buttermilk setting as morning and evening 2x3 gr the day on which high-dose furosemide was given. Group C: All ascites was poured at once during total RLVP application. As support, 6 g albumin solutions were given per liter of the discharged ascites. Follow-up Period: After discharge from the hospital, patients were observed as outpatients once biweekly for 2 months, then monthly for 14 months.
Sample Collection and Laboratory Analysis
Venous blood from all study subjects was collected in EDTA-containing and no-additives-containing tubes. The plasma and serum were separated by low-speed centrifugation (4°C, 1200 g and 10 minutes). Grossly hemolyzed or lipemic specimens were not used. Serum levels of bilirubin, creatinine, sodium, potassium, uric ascites and albumin and urine levels of sodium and potassium were measured in an Abbott AEROSET autoanalyzer using Abbott kits (Abbott Laboratories, Abbott Park, IL, USA).
Prothrombin time (PT) was measured using a Coagumaster (Hitachi, Tokyo, Japan) and Simplastin Automated (Lot no. 100313, ISI= 2.16, Organon Teknika, Durham, NC, USA) as the reagent. PT-INR was calculated by the formula: PT-INR= (PT seconds of patient's plasma/PT seconds of normal control).
All patients were tested for viral hepatitis (HBV and HCV). Chest X-rays were taken in patients with pleural effusion. Daily performed follow-ups included weight, urine output and supine waist circumference (WC). Arterial blood pressure and pulse rate are measured bid. After the start of treatment (on 3 rd and 6 th days at the hospital and 14 th day), serum and urine creatinine and sodium and potassium levels were analyzed.
After the initial outpatient assessment, use of oral salt and oral diuretics were continued at home at the level of dose previously administered, when body weight and WC increased.
Predicted undesirable side effects related to applications I.v. high-dose infusion of furosemide was more common, particularly in clinical cardiology procedure. Undesirable side effects generally involved fluid and electrolyte loss, which can be checked during the hospitalization. Since oral high-dose diuretic was calculated close to i.v. dose, it had similar side effects profile that could be controlled.
• Efficacy endpoints were as follows:
• reduction in body weight at discharge; • relief of overt ascites at discharge 3 days after the end of diuretic treatment period (orally or i.v.) or after the last RLVP (ascites graded according to IAC criteria) ; • improvement in Child Pugh score at discharge; • improvement of MELD score at discharge; • decline in hospital stay and hospitalization;
• improvement in any co-existing fluid overload (pretibial edema, PE),
• improvement in HE, and,
• decline in incidence of SBP. This study was approved by Hatay Mustafa Kemal University Medical Faculty institutional review board and ethics committee. The written informed consent, in accordance with the Helsinki Declaration was obtained from all participants at inclusion.
Statistical Analysis
All parametric results are expressed as mean±standard deviation (SD to participate in the study and were randomized into three groups: 25 were assigned to Group A, 26 to Group B and 27 Group C. Participants had no history of exposure to toxins or usage of other drug.
Laboratory and clinical parameters
As shown in Table 1 , after the treatment, a significant increase was observed in daily diuresis in Groups A and B (p<0.001 for both Groups A and B). Daily sodium output increased in Group A and B, with a significant difference for both (p <0.001). Serum sodium and uric ascites levels increased significantly (p <0.001 for both Groups A and B) and body weight increased significantly in all groups (p < 0.001 for both Groups A and B; p= 0.010 for Group C). Serum bilirubin level and INR increased significantly in Group C (p <0.001 for both metabolites). Urinary sodium levels were significantly increased which could represent an improvement of diuretic response in patients of Group A and B (p <0.001 for both).
In Group B, the changes in MELD and Child-Pugh scores were significantly higher (p<0.001) than those seen in Group C. There was a significant difference in the degree of improvement of the MELD score between Groups A and B (p= 0.034) (as seen in Table 3 and 4).
Hepatic-encephalopathy
During the follow-up period, 4% of patients in Group A, 23.1% in Group B and 59.3% in Group C experienced one or more episodes of HE (Table 1) . In Group C, the total number of episodes of encephalopathy was significantly greater than during follow-up period (p= 0.001).
Gastrointestinal-bleeding (GI)
During the follow-up period, 16% of patients from Group A, 15.4% from Group B, and 37% from Group C experienced an episode of GI bleeding (Table 2 ); the differences were not statistically significant in Group C when compared individually to Group B (p= 0.119). The source of bleeding was esophageal varices in all patients.
Spontaneous bacterial peritonitis
During the follow-up period, 8% of patients from Group A, 7.7% from Group B and 48.1% from Group C experienced an episode of SBP (Table 1) ; the episodes were significantly more frequent in Group C than group B (p= 0.002). Also, during the follow-up period, there was a significant increase in number of SBP patients in Group C (p= 0.004). (Table 3 and 4) . Also, hospital stay (as day) was lowest in Group B when compared individually with the other two groups (p =0.00).
Hospitalization Number and Hospital Stay
Survival
As seen in Table 2 , six patients in Group A (24%) died during the follow-up period (12-20 months); three patients died of GI, one of pneumonia, one of SBP andone of sepsis. Four patients in group B (15.4%) died -that was the lowest mortality rate among all groups and during the follow-up period (6-30 months); two patients died of GI, one of sepsis and one of hepatorenal syndrome. Group C had the highest mortality rate, with 12 patient deaths (44.4%) including nine patients (33.3% ) who died while still in the hospital. The main cause of death in the RLVP group was hepatorenal syndrome (41.6% of deaths).
Other Results
The most severe pretibial edema, level (III), was mostly observed in Group B (30.7%). There was no significant difference among groups in INR before the trial. Acute renal failure and hepatorenal syndrome were more in Group C among all other groups (as seen in Tables 2) .
Discussion
RA is defined by the lack of response to a low sodium diet and diuretics or occurrence of serious diuretic induced complications [9] . In other words, RA may not be mobilized or early reappearance after treatment and may not be prevented by medical therapies. Several different therapeutic approaches have been tested in cirrhotic patients with RA; including, surgical portocaval anastomosis [11] , paracentesis with i.v. albumin infusion [12] , transjugular intrahepatic portacaval shunt [12] and diuretics [13] . Cirrhotic patients with RA are characterized by renal sodium and water retention with edema formation. Abnormalities influence renal function that antagonized diuretics effects. Mobilization of extra vascular fluid through the osmotic action of HSS and rapid excretion of the volume by the support of diuretics is the most often used treatments of cirrhosis. HSS is based on the quick elevation of NaCl concentration with increased osmotic pressure, volume mobilization into vascular compartment and increasing in renal blood flow that stimulates renal perfusion. Spironolactone and loop diuretics were associated with HSS to get success. The effective dosage of diuretics resulted in increasing of renin activity and also serum aldosterone level.
Aldosterone regulates blood pressure and increases reabsorption of ions and water in the kidney to cause the conservation of sodium, secretion of potassium, increase in water retention, blood pressure, and blood volume. HSS can increase the efficiency of diuretic treatment by expanding arterial circulation volume and increasing distribution of the sodium.
Generally, paracentesis is the first choice treatment of RA. Few studies have compared paracentesis versus diuretics+HSS. Quintero et al. [14] studied with randomly-assigned patients to treatment with either paracentesis+i.v. albumin infusion or diuretics, showing similar outcomes between two groups. Salerno et al. [15] stated that repeated paracentesis with human albumin replacement was safe, effective and more rapid than traditional diuretic therapy in treating tense ascites. These studies hypothesized that some diuretics may also impair the urea cycle leading to decreased hepatic transformation of ammonia to urea. There are some disadvantages of repeated paracentesis: early phase healing was rapidly followed by post-paracentesis HE, GI bleeding and SBP [16] , which are the main reasons of death in RA. In the present study, we found that HE (p= 0.017) and SBP (p= 0.002) were significantly better in Group B compared with Groups C (Table 4) . According to the results, the relative risk of GI was 2.4 times greater in Group C patients, compared with Group B patients. Comparison between Groups B and C showed that diuretics+oral salt also provided a clinical benefit; patients treated with diuretics+oral salt had a significantly better survival and lower morbidity than patients treated with RLVP.
Another factor which contributes to the improvement in survival reduces the morbidity of patients treated with diuretics+ salt used orally might have been the noticeable reduction in the number of RLVP intervention during the treatment period. Even if RLVP procedures are combined with an albumin infusion, it carries a risk of post-paracentesis circulatory dysfunction complication that causes reduces long-term survival [3, 17] . These RLVP risks should be eliminated to improve patient survival. Alternative RA t r e a t m e n t m e t h o d s l i k e p o s t -p a r a c e n t e s i s parenteral-nutritional-support with a balanced oral diet and an evening protein snack are not sufficient to reduce HE, SBP and GI bleedings [18] .
On the other hand, recent studies support the effectiveness of alternative diuretics. Preliminary studies have tested the safety and tolerability of HSS and furosemide combination [19] , and suggest that combination therapy is preferred instead of treatment with furosemide alone [20] . In patients with RA, ascites level, PE, and leg edema were significantly better in patients treated with high-dose furosemide+HSS [13] . Side effects of the treatment can be managed with suggested strategies [13] . This method has been quite effective for congestive heart failure (CHF) associated with compensated cirrhosis [21] . Licata et al. demonstrated, in their work with RA, that CHF patients that administration of i.v. furosemide and HSS is a safe and effective treatment [9, 22] . The preliminary study in 2003 showed that the group with HSS treatment in combination with furosemide responded better to diuresis and natriuresis due to the increased sodium. By the end of the year, the mortality rate declined from 55% to 13% [22] . In 2009, the same research team implemented HSS treatment with high-dose furosemide to 60 of 84 patients with RA [8] . In that pilot study, there has been a significant increase in diuresis (p˂0.001), improvement in Child-plug score (p= 0.004), considerable decline in the ascites at discharge (p˂0.001) and pretibial edema (p˂0.001).
On the other hand, there was no statistically significant reduction in GI bleedings (p= 0.07), hospitalization days (p= 0.68) or HE (p= 0.67). HE was as a result of plasma volume expander through osmotic effect of observed high efficacy sodium chloride. It has been showed that diuretics+HSS treatment was generally more reliable and effective alternative than RLVP, but there was no significant reduction in hospitalization stay (9.4±2.2 days) [9] . In the present study, compared with the furosemide+HSS group, patients with high-dose furosemide+salt orally group had significantly better values for hospitalization number (p= 0.001) and hospital stay (p< 0.001).
In conclusion, we evaluated the efficacy and safety of high-dose furosemide+salt orally with HSS+furosemide (i.v.) a n d r e p e a t e d p a r a c e n t e s i s w i t h R A . H i g h -d o s e furosemide+salt orally treatment method seems possible and practical. So, it should be considered as an alternative treatment -leading to improvement in HE, decline in the incidence of SBP and GI bleeding, improvement in MELD and Child-Pugh scores, decline in hospital stay and hospitalization duration, and prolong the lives of RA patients.
Limitations of the Study
Nevertheless, further studies are needed to confirm our findings and proceed and evaluate the limitations of treatments. Some limitations of the prospective study must be taken into account. First, our study was carried out with a relatively few patients. Ideally, it should be repeated with more patients in each group. Second, the follow-up period should be longer to evaluate long-term success of treatments.
